December 10, 2012Transplant Trialsadmin Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled®, propylene glycol-free high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.
